| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.92 [0.85, 1.00] | | < 1 | | 0% | 5 studies (5/-) | 97.9 % | some concern | not evaluable | moderate | crucial | - |
| progression or deaths (PFS) | 0.91 [0.69, 1.20] | | < 1 | | 87% | 4 studies (4/-) | 74.7 % | some concern | not evaluable | moderate | important | - |
| CRR | 1.96 [1.21, 3.17] | | > 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
| DOR | 0.38 [0.18, 0.79] | | < 1 | | 83% | 3 studies (3/-) | 99.5 % | some concern | not evaluable | moderate | non important | - |
| objective responses (ORR) | 0.66 [0.37, 1.17] | | > 1 | | 94% | 5 studies (5/-) | 7.9 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.52 [0.03, 8.39] | | < 1 | | 87% | 2 studies (2/-) | 67.6 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-4) | 0.35 [0.11, 1.05] | | < 1 | | 97% | 3 studies (3/-) | 96.9 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-5) | 0.76 [0.19, 3.00] | | < 1 | | 96% | 2 studies (2/-) | 65.4 % | some concern | not evaluable | moderate | non important | - |
| AE leading to death (grade 5) | 2.15 [1.27, 3.66] | | < 1 | | 60% | 4 studies (4/-) | 0.2 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.70 [0.32, 1.54] | | < 1 | | 95% | 5 studies (5/-) | 81.2 % | some concern | not evaluable | moderate | non important | - |
| SAE (any grade) | 0.96 [0.78, 1.19] | | < 1 | | 36% | 3 studies (3/-) | 63.8 % | some concern | not evaluable | moderate | non important | - |
| STRAE (any grade) | 0.67 [0.39, 1.15] | | < 1 | | 90% | 5 studies (5/-) | 92.8 % | some concern | serious | moderate | non important | - |
| TRAE (any grade) | 0.16 [0.06, 0.47] | | < 1 | | 93% | 4 studies (4/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.21 [0.05, 0.84] | | < 1 | | 99% | 5 studies (5/-) | 98.6 % | some concern | serious | moderate | non important | - |
| TRAE leading to death (grade 5) | 1.33 [0.64, 2.77] | | < 1 | | 0% | 5 studies (5/-) | 22.5 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 0.46 [0.26, 0.79] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 3.64 [0.16, 81.12] | | < 1 | | 0% | 1 study (1/-) | 21.0 % | NA | not evaluable | | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 0.45 [0.02, 13.55] | | < 1 | | 0% | 1 study (1/-) | 67.4 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 1.32 [0.15, 11.32] | | < 1 | | 0% | 3 studies (3/-) | 40.1 % | some concern | not evaluable | moderate | non important | - |
| Alopecia TRAE (grade 3-4) | 1.82 [0.06, 54.35] | | < 1 | | 0% | 1 study (1/-) | 36.7 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 0.16 [0.04, 0.62] | | < 1 | | 95% | 5 studies (5/-) | 99.6 % | some concern | serious | moderate | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Arthritis TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 0.68 [0.29, 1.59] | | < 1 | | 57% | 5 studies (5/-) | 81.3 % | some concern | serious | moderate | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.45 [0.02, 13.55] | | < 1 | | 0% | 1 study (1/-) | 67.4 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 2.60 [0.58, 11.65] | | < 1 | | 0% | 3 studies (3/-) | 10.6 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.75 [0.16, 3.48] | | < 1 | | 0% | 3 studies (3/-) | 64.1 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.81 [0.32, 2.01] | | < 1 | | 0% | 5 studies (5/-) | 67.8 % | some concern | not evaluable | moderate | non important | - |
| Diabetes TRAE (grade 3-4) | 1.68 [0.22, 13.01] | | < 1 | | 0% | 3 studies (3/-) | 31.2 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.89 [0.41, 1.92] | | < 1 | | 0% | 3 studies (3/-) | 61.5 % | some concern | not evaluable | moderate | non important | - |
| Dyspnoea TRAE (grade 3-4) | 3.64 [0.16, 81.12] | | < 1 | | 0% | 1 study (1/-) | 21.0 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.74 [0.32, 1.69] | | < 1 | | 45% | 5 studies (5/-) | 76.5 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.15 [0.01, 3.01] | | < 1 | | 0% | 1 study (1/-) | 89.0 % | NA | not evaluable | | non important | - |
| Gastritis TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 1.82 [0.06, 54.35] | | < 1 | | 0% | 1 study (1/-) | 36.7 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 3.07 [0.47, 19.99] | | < 1 | | 0% | 3 studies (3/-) | 12.2 % | some concern | not evaluable | moderate | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 0.45 [0.02, 13.55] | | < 1 | | 0% | 1 study (1/-) | 67.4 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.32 [0.15, 11.32] | | < 1 | | 0% | 3 studies (3/-) | 40.1 % | some concern | not evaluable | moderate | non important | - |
| Hypophysitis TRAE (grade 3-4) | 2.72 [0.39, 19.09] | | < 1 | | 0% | 3 studies (3/-) | 15.9 % | some concern | not evaluable | moderate | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 2.25 [0.31, 16.26] | | < 1 | | 0% | 3 studies (3/-) | 21.2 % | some concern | not evaluable | moderate | non important | - |
| Increase AST TRAE (grade 3-4) | 0.91 [0.13, 6.48] | | < 1 | | 0% | 1 study (1/-) | 53.9 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 2.74 [0.28, 26.45] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 6.46 [0.79, 52.82] | | < 1 | | 0% | 1 study (1/-) | 4.2 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.07 [0.00, 1.54] | | < 1 | | 84% | 3 studies (3/-) | 95.2 % | some concern | not evaluable | moderate | non important | - |
| Myocarditis TRAE (grade 3-4) | 2.19 [0.30, 15.87] | | < 1 | | 0% | 3 studies (3/-) | 21.9 % | some concern | not evaluable | moderate | non important | - |
| Myositis TRAE (grade 3-4) | 1.31 [0.15, 11.23] | | < 1 | | 0% | 3 studies (3/-) | 40.3 % | some concern | not evaluable | moderate | non important | - |
| Nausea TRAE (grade 3-4) | 0.53 [0.21, 1.38] | | < 1 | | 31% | 5 studies (5/-) | 90.2 % | some concern | not evaluable | moderate | non important | - |
| Nephritis TRAE (grade 3-4) | 2.59 [0.39, 17.31] | | < 1 | | 0% | 3 studies (3/-) | 16.4 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.16 [0.04, 0.70] | | < 1 | | 90% | 5 studies (5/-) | 99.3 % | some concern | serious | moderate | non important | - |
| Pancreatitis TRAE (grade 3-4) | 2.93 [0.43, 19.90] | | < 1 | | 0% | 3 studies (3/-) | 13.7 % | some concern | not evaluable | moderate | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.11 [0.01, 2.13] | | < 1 | | 0% | 1 study (1/-) | 92.5 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 3.69 [0.90, 15.07] | | < 1 | | 0% | 3 studies (3/-) | 3.5 % | some concern | not evaluable | moderate | non important | - |
| Pruritic rash TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 2.12 [0.45, 10.02] | | < 1 | | 0% | 5 studies (5/-) | 17.2 % | some concern | serious | moderate | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.23 [0.01, 5.02] | | < 1 | | 0% | 1 study (1/-) | 82.3 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 2.48 [0.66, 9.36] | | < 1 | | 0% | 5 studies (5/-) | 9.1 % | some concern | not evaluable | moderate | non important | - |
| Sarcoidosis TRAE (grade 3-4) | 1.05 [0.07, 16.88] | | < 1 | | 0% | 2 studies (2/-) | 48.5 % | some concern | not evaluable | moderate | non important | - |
| Sepsis TRAE (grade 3-4) | 0.91 [0.06, 14.56] | | < 1 | | 0% | 1 study (1/-) | 52.7 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 2.46 [0.72, 8.32] | | < 1 | | 0% | 2 studies (2/-) | 7.5 % | some concern | not evaluable | moderate | non important | - |
| Stevens-Johnson syndrome TRAE (grade 3-4) | 1.82 [0.06, 54.35] | | < 1 | | 0% | 1 study (1/-) | 36.7 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.20 [0.05, 0.71] | | < 1 | | 85% | 5 studies (5/-) | 99.4 % | some concern | serious | moderate | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.34 [0.16, 11.49] | | < 1 | | 0% | 3 studies (3/-) | 39.6 % | some concern | not evaluable | moderate | non important | - |
| Vomiting TRAE (grade 3-4) | 0.34 [0.06, 1.92] | | < 1 | | 60% | 3 studies (3/-) | 88.9 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
| Anaemia AE (grade 3-4) | 0.29 [0.02, 3.86] | | < 1 | | 99% | 2 studies (2/-) | 82.3 % | some concern | not evaluable | moderate | non important | - |
| Asthenia AE (grade 3-4) | 0.88 [0.32, 2.41] | | < 1 | | 78% | 2 studies (2/-) | 59.5 % | some concern | not evaluable | moderate | non important | - |
| Fatigue AE (grade 3-4) | 0.41 [0.14, 1.17] | | < 1 | | 75% | 2 studies (2/-) | 95.2 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia AE (grade 3-4) | 0.41 [0.01, 11.84] | | < 1 | | 81% | 2 studies (2/-) | 69.7 % | some concern | not evaluable | moderate | non important | - |
| Hypertension AE (grade 3-4) | 1.16 [0.29, 4.59] | | < 1 | | 77% | 2 studies (2/-) | 41.4 % | some concern | not evaluable | moderate | non important | - |
| Leucopenia AE (grade 3-4) | 0.14 [0.00, 5.94] | | < 1 | | 86% | 2 studies (2/-) | 84.5 % | some concern | not evaluable | moderate | non important | - |
| Nausea AE (grade 3-4) | 0.26 [0.04, 1.67] | | < 1 | | 67% | 2 studies (2/-) | 92.2 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia AE (grade 3-4) | 0.08 [0.00, 29.10] | | < 1 | | 94% | 2 studies (2/-) | 79.0 % | some concern | not evaluable | moderate | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.14 [0.00, 12.34] | | < 1 | | 95% | 2 studies (2/-) | 79.8 % | some concern | not evaluable | moderate | non important | - |
| Vomiting AE (grade 3-4) | 0.36 [0.04, 2.88] | | < 1 | | 73% | 2 studies (2/-) | 83.2 % | some concern | not evaluable | moderate | non important | - |
